The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Randomized Phase IIB Trial of BLP25 Liposome Vaccine in Stage IIIB and IV Non–Small-Cell Lung Cancer
Open accessAbstract
Purpose: To evaluate the effect of BLP25 liposome vaccine (L-BLP25) on survival and toxicity in patients with stage IIIB and IV non–small-cell lung cancer (NSCLC). Secondary objectives included health-related quality of life (QOL) and immune responses elicited by L-BLP25. Patients and Methods: Patients with an Eastern Cooperative Oncology Group performance status of 0 to 2 and stable or responding stage IIIB or IV NSCLC after any first-line chemotherapy were prestratified by stage and randomly assigned to either L-BLP25 plus best supportive care (BSC) or BSC alone. Patients in the L-BLP25 arm received a single intravenous dose of cyclophosphamide 300 mg/m 2 followed by eight weekly subcutaneous immunizations with L-BLP25 (1,000 μg). Subsequent immunizations were administered at 6-week intervals. Results: The survival results indicate a median survival time of 4.4 months longer for patients randomly assigned to the L-BLP25 arm (88 patients) compared with patients assigned to the BSC arm (83 patients; adjusted hazard ratio [HR] = 0.739; 95% CI, 0.509 to 1.073; P = .112). The greatest effect was observed in stage IIIB locoregional (LR) patients, for whom the median survival time for the L-BLP25 arm has not yet been reached compared with 13.3 months for the BSC arm (adjusted HR = 0.524; 95% CI, 0.261 to 1.052; P = .069). No significant toxicity was observed. QOL was maintained longer in patients on the L-BLP25 arm. Conclusion: L-BLP25 maintenance therapy in patients with advanced NSCLC is feasible with minimal toxicity. The survival difference of 4.4 months observed with the vaccine did not reach statistical significance. In the subgroup of patients with stage IIIB LR disease, a strong trend in 2-year survival in favor of L-BLP25 was observed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brady, M. J., Cella, D. F., Mo, F., Bonomi, A. E., Tulsky, D. S., Lloyd, S. R., Deasy, S., Cobleigh, M., & Shiomoto, G. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.974 · Cited by 1,752
Giaccone, G., Herbst, R. S., Manegold, C., Scagliotti, G., Rosell, R., Miller, V., Natale, R. B., Schiller, J. H., von Pawel, J., Pluzanska, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.001 · Cited by 1,716
Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V., Manegold, C., Scagliotti, G., Rosell, R., Oliff, I., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,707
Herbst, R. S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B. E., Sandler, A., Kris, M. G., Tran, H. T., Klein, P., Li, X., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.840 · Cited by 1,490
Pfister, D. G., Johnson, D. H., Azzoli, C. G., Sause, W., Smith, T. J., Baker Jr, S., Olak, J., Stover, D., Strawn, J. R., Turrisi, A. T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.053 · Cited by 1,413
Cella, D. F., Bonomi, A. E., Lloyd, S. R., Tulsky, D. S., Kaplan, E., & Bonomi, P. (1995) · Lung Cancer · doi:10.1016/0169-5002(95)00450-f · Cited by 750
Heterogeneity of mucin gene expression in normal and neoplastic tissues.
Ho, S. B., Niehans, G. A., Lyftogt, C. T., Yan, P., Cherwitz, D. L., Gum, E. T., Dahiya, R., & Kim, Y. S. (1993) · PubMed · Cited by 665
Machiels, J.-P., Reilly, R. T., Emens, L. A., Ercolini, A. M., Lei, R. Y., Weintraub, D., Okoye, F. I., & Jaffee, E. M. (2001) · PubMed · Cited by 453
Gatzemeier, U., Groth, G., Butts, C., Van Zandwijk, N., Shepherd, F., Ardizzoni, A., Barton, C., Ghahramani, P., & Hirsh, V. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh031 · Cited by 388
Self-citationSocinski, M. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1335 · Cited by 379
(1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.8.2996 · Cited by 355
Breathnach, O. S., Freidlin, B., Conley, B., Green, M. R., Johnson, D. H., Gandara, D. R., O’Connell, M., Shepherd, F. A., & Johnson, B. E. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1734 · Cited by 354
Gatzemeier, U., Pluzanska, A., Szczęsna, A., Kaukel, E., Roubec, J., Brennscheidt, U., Rosa, F. D., Mueller, B., & von Pawel, J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.7010 · Cited by 312
Smith, I. E., O’Brien, M. E. R., Talbot, D. C., Nicolson, M. C., Mansi, J. L., Hickish, T. F., Norton, A., & Ashley, S. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1336 · Cited by 308
Self-citationNemunaitis, J., Sterman, D., Jablons, D., Smith, J. W., Fox, B., Maples, P., Hamilton, S., Borellini, F., Lin, A., Morali, S., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh028 · Cited by 244
Vaccine-Induced CD4+ T Cell Responses to MAGE-3 Protein in Lung Cancer Patients
Atanackovic, D., Altorki, N. K., Stockert, E., Williamson, B., Jungbluth, A. A., Ritter, E., Santiago, D., Ferrara, C. A., Matsuo, M., Selvakumar, A., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.3289 · Cited by 184
Gene-based vaccines and immunotherapeutics
Liu, M., Acres, B., Balloul, J.-M., Bizouarne, N., Paul, S., Slos, P., & Squiban, P. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404845101 · Cited by 182
MacLean, G. D., Miles, D. W., Rubens, R. D., Reddish, M. A., & Longenecker, B. M. (1996) · Journal of Immunotherapy · doi:10.1097/00002371-199607000-00006 · Cited by 161
Herbst, R. S., Prager, D., Hermann, R., Miller, V. A., Fehrenbacher, L., Hoffman, P. C., Johnson, B. E., Sandler, A. B., MASS, R. D., & Johnson, D. H. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.7011 · Cited by 146
Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer
Bass, K. K., & Mastrangelo, M. J. (1998) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050498 · Cited by 96
Guan, H. H., Budzynski, W. A., Koganty, R. R., Krantz, M. J., Reddish, M. A., Rogers, J. A., Longenecker, B. M., & Samuel, J. (1998) · Bioconjugate Chemistry · doi:10.1021/bc970183n · Cited by 96
Cited by
Non-small cell lung cancer: current treatment and future advances
Zappa, C., & Mousa, S. A. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.06.07 · Cited by 1,944
Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00346-0 · Cited by 1,581
Melief, C. J. M., van Hall, T., Arens, R., Ossendorp, F., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,164
Lung cancer immunotherapy: progress, pitfalls, and promises
Lahiri, A., Maji, A., Potdar, P. D., Singh, N., Parikh, P., Bisht, B., Mukherjee, A., & Paul, M. K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01740-y · Cited by 1,102
Lynch, T. J., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., Sebastian, M., Neal, J., Lu, H., Cuillerot, J.-M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.4032 · Cited by 1,002
Metadata
- Authors
- Butts, C., Murray, N., Maksymiuk, A., Goss, G., Marshall, E., Soulières, D., Cormier, Y., Ellis, P., Price, A., Sawhney, R., Davis, M., Mansi, J., Smith, C., Vergidis, D., Ellis, P., MacNeil, M., & Palmer, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-09-20
- Volume
- 23
- Issue
- 27
- Pages
- 6674-6681
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2114300639
- Cited by
- 428
- References
- 21
- FWCI
- 13.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.